Literature DB >> 9581211

Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction.

Y I Sheline1, K Miller, M E Bardgett, J G Csernansky.   

Abstract

The authors sought to determine the relationships between cerebrospinal fluid (CSF) levels of three neurotransmitter monoamine metabolites and cognitive function. CSF was collected from subjects with dementia of the Alzheimer's type ([DAT] n = 28) and control subjects (n = 10) for determination of CSF 5-hydroxyindole acetic acid (5-HIAA), 3-methoxy-4-hydroxy-phenylglycol (MHPG), and homovanillic acid (HVA) levels. All subjects underwent systematic assessment to determine cognitive function. Subjects with DAT had higher concentrations of CSF MHPG. In the overall sample, cognitive function was inversely correlated with CSF levels of MHPG but not with 5-HIAA or HVA. Within the DAT sample, these correlations did not achieve significance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581211

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  5 in total

1.  Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.

Authors:  Heidi I L Jacobs; John Alex Becker; Kenneth Kwong; Diana Munera; Liliana Ramirez-Gomez; Nina Engels-Domínguez; Justin S Sanchez; Clara Vila-Castelar; Ana Baena; Reisa A Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz
Journal:  Alzheimers Dement       Date:  2022-03-17       Impact factor: 16.655

2.  Associations among locus coeruleus catecholamines, tau pathology, and memory in aging.

Authors:  Claire J Ciampa; Jourdan H Parent; Theresa M Harrison; Rebekah M Fain; Matthew J Betts; Anne Maass; Joseph R Winer; Suzanne L Baker; Mustafa Janabi; Daniella J Furman; Mark D'Esposito; William J Jagust; Anne S Berry
Journal:  Neuropsychopharmacology       Date:  2022-01-15       Impact factor: 8.294

3.  Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.

Authors:  Heidi I L Jacobs; Joost M Riphagen; Inez H G B Ramakers; Frans R J Verhey
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

4.  Elevated Norepinephrine Metabolism Gauges Alzheimer's Disease-Related Pathology and Memory Decline.

Authors:  Joost M Riphagen; Maxime van Egroo; Heidi I L Jacobs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

5.  Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease.

Authors:  Josef Marksteiner; Michaela Defrancesco; Christian Humpel
Journal:  Front Aging Neurosci       Date:  2022-09-29       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.